NorthWest Biotherapeutics Inc (NWBO)

[maverick_1]

the screening halt in August slipped up on them... and someone, IMO, should have foreseen that. Perhaps that would be Meghan Swardstrom.

Sure enough like I pointed out at the outset of this thread, Meghan Swardstrom after 5 yrs with NWBO, in a matter of a few weeks since that post is working for another firm after 5 yrs with NWBO while during her last year apparently working also doing full time consulting for another firm:https://www.linkedin.com/in/meghan-swardstrom-246b67?authType=name&authToken=DLPK&trk=prof-sb-browse_map-name

Director, Clinical Trials
Nohla Therapeutics
July 2016 – Present (1 month)Seattle
Principal Consultant
Emerald Clinical Consulting
January 2015 – Present (1 year 7 months)Greater Seattle Area
Sr. Director, Clinical Development and Operations
Northwest Biotherapeutics
November 2014 – July 2016 (1 year 9 months)
Director, Clinical Operations
Northwest Biotherapeutics
July 2011 – November 2014 (3 years 5 months)Greater Seattle Area

Given the above, it maybe coincidental that my instincts of not having a seasoned PH3 FDA Clinical Affairs/Clinical Trials or CMO, maybe a key factor for the Screening Halt...

See: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=123741359